All In Biotech

NDA 215487 · Scienture

Rezenopy

Naloxone Hydrochloride · Nasal

Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Apr 19, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

682

129 Phase 3, 31 recruiting

FAERS reports

809

510 serious, 100 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 3, 2026.

REZENOPY nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. REZENOPY nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. REZENOPY nasal spray is not a substitute for emergency medical care. REZENOPY nasal spray is an opioid antagonist for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ( 1 ) REZENOPY nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) REZENOPY nasal spray is not a substitute for emergency medical care. ( 1 )

Mechanism: Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. Naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation, and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 19, 2024 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • REZENOPY · NALOXONE HYDROCHLORIDE 10MG/SPRAY · SPRAY, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Naloxone" as an intervention, any sponsor and status, largest first.

All 682 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue90
  • nausea73
  • headache54
  • drug ineffective52
  • diarrhoea51
  • off label use50
  • pain50
  • death47
  • dyspnoea47
  • product dose omission issue46
  • asthenia37
  • rash36

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20054
20063
20071
20081
20096
20115
201215
20131
20143
20153
201610
201719
201835
201941
202049
202128
202258
2023120
2024128
2025157
2026119

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,733 on PubMed

Sponsor: Scienture

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.